Woods K - Search Results

1

Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma.

Faridi P, Woods K, Ostrouska S, Deceneux C, Aranha R, Duscharla D, Wong SQ, Chen W, Ramarathinam SH, Lim Kam Sian TCC, Croft NP, Li C, Ayala R, Cebon JS, Purcell AW, Schittenhelm RB, Behren A. Faridi P, et al. Among authors: woods k. Cancer Immunol Res. 2020 Oct;8(10):1322-1334. doi: 10.1158/2326-6066.CIR-19-0894. Epub 2020 Sep 16. Cancer Immunol Res. 2020. PMID: 32938616

2

Tumor-specific T-cell help is associated with improved survival in melanoma.

Woods K, Cebon J. Woods K, et al. Clin Cancer Res. 2013 Aug 1;19(15):4021-3. doi: 10.1158/1078-0432.CCR-13-1349. Epub 2013 Jul 17. Clin Cancer Res. 2013. PMID: 23864163

3

Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment.

Vella LJ, Andrews MC, Behren A, Cebon J, Woods K. Vella LJ, et al. Among authors: woods k. Expert Rev Clin Immunol. 2014 Aug;10(8):1107-23. doi: 10.1586/1744666X.2014.929943. Epub 2014 Jun 17. Expert Rev Clin Immunol. 2014. PMID: 24939732 Review.

4

Evolving role of tumor antigens for future melanoma therapies.

Andrews MC, Woods K, Cebon J, Behren A. Andrews MC, et al. Among authors: woods k. Future Oncol. 2014 Jun;10(8):1457-68. doi: 10.2217/fon.14.84. Future Oncol. 2014. PMID: 25052755 Review.

5

Whole exome sequencing identifies a recurrent RQCD1 P131L mutation in cutaneous melanoma.

Wong SQ, Behren A, Mar VJ, Woods K, Li J, Martin C, Sheppard KE, Wolfe R, Kelly J, Cebon J, Dobrovic A, McArthur GA. Wong SQ, et al. Among authors: woods k. Oncotarget. 2015 Jan 20;6(2):1115-27. doi: 10.18632/oncotarget.2747. Oncotarget. 2015. PMID: 25544760 Free PMC article.

6

Mismatch in epitope specificities between IFNγ inflamed and uninflamed conditions leads to escape from T lymphocyte killing in melanoma.

Woods K, Knights AJ, Anaka M, Schittenhelm RB, Purcell AW, Behren A, Cebon J. Woods K, et al. J Immunother Cancer. 2016 Feb 16;4:10. doi: 10.1186/s40425-016-0111-7. eCollection 2016. J Immunother Cancer. 2016. PMID: 26885372 Free PMC article.

7

The good, the (not so) bad and the ugly of immune homeostasis in melanoma.

da Gama Duarte J, Woods K, Andrews MC, Behren A. da Gama Duarte J, et al. Among authors: woods k. Immunol Cell Biol. 2018 May;96(5):497-506. doi: 10.1111/imcb.12001. Epub 2018 Feb 2. Immunol Cell Biol. 2018. PMID: 29392770 Review.

8

Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette-Guérin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma.

Da Gama Duarte J, Parakh S, Andrews MC, Woods K, Pasam A, Tutuka C, Ostrouska S, Blackburn JM, Behren A, Cebon J. Da Gama Duarte J, et al. Among authors: woods k. Front Immunol. 2018 Mar 2;9:411. doi: 10.3389/fimmu.2018.00411. eCollection 2018. Front Immunol. 2018. PMID: 29552014 Free PMC article. Clinical Trial.

9

Flt3 ligand expands CD4+ FoxP3+ regulatory T cells in human subjects.

Klein O, Ebert LM, Zanker D, Woods K, Tan BS, Fucikova J, Behren A, Davis ID, Maraskovsky E, Chen W, Cebon J. Klein O, et al. Among authors: woods k. Eur J Immunol. 2013 Feb;43(2):533-9. doi: 10.1002/eji.201242603. Epub 2012 Dec 5. Eur J Immunol. 2013. PMID: 23124877 Free article.

10

MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells.

Vella LJ, Pasam A, Dimopoulos N, Andrews M, Knights A, Puaux AL, Louahed J, Chen W, Woods K, Cebon JS. Vella LJ, et al. Among authors: woods k. Cancer Immunol Res. 2014 Apr;2(4):351-60. doi: 10.1158/2326-6066.CIR-13-0181. Epub 2014 Jan 17. Cancer Immunol Res. 2014. PMID: 24764582

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

846 results

Search Page